- Advertisement -
FOSTER CITY, Calif.–(BUSINESS WIRE)—- $GERN–Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025, covering an aggregate of 1,579,500 shares of its common stock, consisting of stock options to…
Click here to view the original article.
